Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART‐experienced patients

José Ignacio Bernardino(Hospital Universitario La Paz), Juan González‐García(Hospital Universitario La Paz), Eulalia Valencia, Jorge Vergas(Hospital Clínico San Carlos), Francisco Xavier Zamora(Hospital La Paz Institute for Health Research), Vicente Estrada(Instituto de Salud Carlos III), María Jesús Téllez(Hospital Clínico San Carlos), V. Moreno

Journal of the International AIDS Society

November 1, 2014

10.7448/ias.17.4.19787

Cited by 4

Related Papers

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy

|JAMA|2016|1.4k

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

|The Lancet|2019|1k

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19

|JAMA|2021|728

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

|The Lancet|2006|343

Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals

|Mucosal Immunology|2014|332